The risks of stroke and peripheral artery disease (PAD) were higher in the group treated with SGLT2-i relative to the group treated with GLP1-RA, HR 1.44 (95% CI 0.99–2.08) and 1.68 (95% CI 1.04–2.72), respectively. The gene discussed is SLC5A2; the disease is Stroke.